Scopolamine NDC 70710-1846

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1846Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1846Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
70710-1846-2	70710184602	10 POUCH in 1 CARTON (70710-1846-2) / 1 PATCH in 1 POUCH / 3 d in 1 PATCHMarketed from Sep 5, 2024
70710-1846-4	70710184604	4 POUCH in 1 CARTON (70710-1846-4) / 1 PATCH in 1 POUCH (70710-1846-1) / 3 d in 1 PATCHMarketed from Sep 5, 2024
70710-1846-7	70710184607	24 POUCH in 1 CARTON (70710-1846-7) / 1 PATCH in 1 POUCH / 3 d in 1 PATCHMarketed from Sep 5, 2024

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Scopolamine
Generic name (nonproprietary): scopolamine
Active ingredients: Scopolamine — 1 mg/3d
Dosage form: Patch, Extended release
Route: Transdermal
Labeler: Zydus Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217893
Marketing start: Sep 5, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Cholinergic Antagonists (Mechanism)
Identifiers: Product ID 70710-1846_12f01688-9740-4229-b196-f51cff21a122SPL ID 12f01688-9740-4229-b196-f51cff21a122SPL set ID 62d8332e-b8d2-4d13-8071-978d57e51928RxCUI 226552UNII DL48G20X8X
Pharmacologic class: Anticholinergic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Transdermal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470710184602 followed by a unit qualifier and the quantity

Package 70710-1846-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 23, 2025.

Indications (excerpt from the label)

Scopolamine transdermal system is indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. ( 1 ) post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217893

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217893
Product	Strength	Form · route	Labeler	Product NDC
Scopolamine	Scopolamine 1 mg/3d	Patch, Extended releaseTransdermal	Zydus Lifesciences Limited	70771-1787